BR112016025009A2 - anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície - Google Patents
anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfícieInfo
- Publication number
- BR112016025009A2 BR112016025009A2 BR112016025009A BR112016025009A BR112016025009A2 BR 112016025009 A2 BR112016025009 A2 BR 112016025009A2 BR 112016025009 A BR112016025009 A BR 112016025009A BR 112016025009 A BR112016025009 A BR 112016025009A BR 112016025009 A2 BR112016025009 A2 BR 112016025009A2
- Authority
- BR
- Brazil
- Prior art keywords
- mers
- antibodies
- surface protein
- bind
- present
- Prior art date
Links
- 102000018697 Membrane Proteins Human genes 0.000 title abstract 4
- 108010052285 Membrane Proteins Proteins 0.000 title abstract 4
- 208000001528 Coronaviridae Infections Diseases 0.000 title 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 241000004176 Alphacoronavirus Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Abstract
a presente invenção refere-se aos anticorpos monoclonais que se ligam a síndrome respiratória do oriente médio - coronavírus (mers-cov) do pico de proteína, e aos métodos de utilização. em várias modalidades da presente invenção, os anticorpos são anticorpos completamente humanos que se ligam a proteína de superfície "spike" de mers-cov. em algumas modalidades, os anticorpos da presente invenção são úteis para inibir ou neutralizar a atividade de mers-cov, proporcionando assim um meio para o tratamento ou prevenção da infecção mers em seres humanos. em algumas modalidades, a presente invenção refere-se a uma combinação de um ou mais anticorpos que se ligam a proteína de superfície "spike" de mers-cov para uso no tratamento de infecção de mers. em certas modalidades, um ou mais anticorpos se ligam a epitopos distintos não concorrentes compreendidos no domínio de ligação do receptor da proteína de superfície "spike" de mers-cov.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462002233P | 2014-05-23 | 2014-05-23 | |
US62/002,233 | 2014-05-23 | ||
US201462004971P | 2014-05-30 | 2014-05-30 | |
US62/004,971 | 2014-05-30 | ||
US201462051717P | 2014-09-17 | 2014-09-17 | |
US62/051,717 | 2014-09-17 | ||
US201462072716P | 2014-10-30 | 2014-10-30 | |
US62/072,716 | 2014-10-30 | ||
PCT/US2015/031800 WO2015179535A1 (en) | 2014-05-23 | 2015-05-20 | Human antibodies to middle east respiratory syndrome -coronavirus spike protein |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016025009A2 true BR112016025009A2 (pt) | 2017-10-24 |
BR112016025009B1 BR112016025009B1 (pt) | 2022-08-02 |
Family
ID=53276323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016025009-5A BR112016025009B1 (pt) | 2014-05-23 | 2015-05-20 | Composição farmacêutica compreendendo anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à proteína spike do mers-cov e seu uso |
Country Status (19)
Country | Link |
---|---|
US (3) | US9718872B2 (pt) |
EP (1) | EP3145539A1 (pt) |
JP (3) | JP6934722B2 (pt) |
KR (1) | KR102371300B1 (pt) |
CN (2) | CN114057869A (pt) |
AU (1) | AU2015264189B2 (pt) |
BR (1) | BR112016025009B1 (pt) |
CA (1) | CA2949438A1 (pt) |
CL (1) | CL2016002934A1 (pt) |
EA (1) | EA036023B1 (pt) |
IL (1) | IL248392B2 (pt) |
JO (1) | JO3701B1 (pt) |
MA (1) | MA40688A (pt) |
MX (1) | MX2016015263A (pt) |
MY (1) | MY180741A (pt) |
PH (1) | PH12016502064A1 (pt) |
SG (1) | SG11201608567YA (pt) |
WO (1) | WO2015179535A1 (pt) |
ZA (1) | ZA201607047B (pt) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
JO3701B1 (ar) * | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
CN106928326B (zh) * | 2015-12-31 | 2019-12-24 | 中国科学院微生物研究所 | 一种基于二聚化的受体结合区亚单位的冠状病毒疫苗 |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
CN107298712B (zh) * | 2016-04-14 | 2020-04-07 | 中国疾病预防控制中心病毒病预防控制所 | 全人源化抗中东呼吸综合征冠状病毒中和抗体 |
TW201815821A (zh) * | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
IL309453A (en) | 2016-08-16 | 2024-02-01 | Regeneron Pharma | A method for quantifying individual antibodies from a mixture |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
IL289895B (en) | 2016-10-25 | 2022-09-01 | Regeneron Pharma | Methods and systems for analysis of chromatography data |
WO2018097603A2 (ko) * | 2016-11-23 | 2018-05-31 | 에스케이케미칼 주식회사 | 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법 |
AU2018210420A1 (en) * | 2017-01-19 | 2019-08-08 | Omniab, Inc. | Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci |
CN110650959B (zh) | 2017-05-22 | 2023-04-18 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
US20190010531A1 (en) | 2017-07-06 | 2019-01-10 | Regeneron Pharmaceuticals, Inc. | Cell culture process for making a glycoprotein |
KR101895228B1 (ko) * | 2017-08-23 | 2018-10-30 | 대한민국 | 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도 |
WO2019067671A1 (en) * | 2017-09-27 | 2019-04-04 | David Weiner | DNA ANTIBODY CONSTRUCTS FOR USE IN CORONAVIRUS RESPIRATORY SYNDROME OF THE MIDDLE EAST |
KR102017217B1 (ko) * | 2017-10-19 | 2019-09-02 | 주식회사 엔케이맥스 | 중동호흡기증후군 코로나바이러스에 대한 항체 및 이를 이용한 항체역가 측정방법 |
SG11202004380QA (en) | 2017-12-22 | 2020-06-29 | Regeneron Pharma | System and method for characterizing drug product impurities |
KR20200115485A (ko) | 2018-01-31 | 2020-10-07 | 리제너론 파마슈티칼스 인코포레이티드 | 약물 생성물 불순물을 특성화하기 위한 시스템 및 방법 |
WO2019151632A1 (ko) * | 2018-01-31 | 2019-08-08 | (주)셀트리온 | 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자 |
KR20190093107A (ko) * | 2018-01-31 | 2019-08-08 | (주)셀트리온 | 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자 |
TWI786265B (zh) | 2018-02-02 | 2022-12-11 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
BR112020013426A2 (pt) | 2018-02-28 | 2020-12-01 | Regeneron Pharmaceuticals, Inc. | métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células |
IL307577A (en) | 2018-03-19 | 2023-12-01 | Regeneron Pharma | In-house capillary electrophoresis tests and reagents |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
US11690907B2 (en) | 2018-06-12 | 2023-07-04 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
US11696948B2 (en) | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
CN110616198B (zh) * | 2018-06-19 | 2021-02-19 | 清华大学 | 一种基于黑猩猩腺病毒68型和MERS-CoV全长膜蛋白的新型冠状病毒疫苗 |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
KR20200020411A (ko) * | 2018-08-17 | 2020-02-26 | 한림대학교 산학협력단 | 메르스 코로나바이러스 s 단백질에 대한 단클론 항체 및 그 용도 |
CN112218877A (zh) | 2018-08-27 | 2021-01-12 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
JP2021535361A (ja) | 2018-08-30 | 2021-12-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | タンパク質複合体を特徴づけるための方法 |
RU2709659C1 (ru) * | 2018-09-06 | 2019-12-19 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета к вирусу ближневосточного респираторного синдрома (варианты) |
KR102007161B1 (ko) * | 2018-11-07 | 2019-08-07 | 대한민국 | 메르스 코로나 바이러스 스파이크 s1 단백질에 특이적으로 결합하는 단클론 항체 |
AU2020208396A1 (en) | 2019-01-16 | 2021-05-20 | Regeneron Pharmaceuticals, Inc. | Methods for identifying free thiols in proteins |
CN113874394B (zh) * | 2019-02-20 | 2024-01-19 | 和铂抗体有限公司 | 抗体 |
US11364276B2 (en) | 2019-03-26 | 2022-06-21 | National Guard Health Affairs | Antiviral peptides for treatment of the middle east respiratory syndrome |
SG11202108451VA (en) * | 2019-04-03 | 2021-09-29 | Regeneron Pharma | Methods and compositions for insertion of antibody coding sequences into a safe harbor locus |
KR102213745B1 (ko) * | 2019-04-16 | 2021-02-09 | 주식회사 바이오앱 | 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법 |
SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
KR20220070262A (ko) * | 2019-09-23 | 2022-05-30 | 서울대학교산학협력단 | 항-mers-cov 항체 및 이의 용도 |
AU2020394428A1 (en) | 2019-11-25 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
IL294765B2 (en) | 2020-01-21 | 2023-12-01 | Regeneron Pharma | Deglycosylation methods for electrophoresis of glycosylated proteins |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
EP4103619A1 (en) | 2020-02-10 | 2022-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss2 antibodies and antigen-binding fragments |
BR112022015707A2 (pt) * | 2020-02-10 | 2022-09-27 | Inst Microbiology Cas | Antígenos de beta-coronavírus, métodos de preparação e usos dos mesmos |
DK3872091T3 (da) | 2020-02-26 | 2023-09-11 | Vir Biotechnology Inc | Antistoffer mod sars-cov-2 |
CN113321713B (zh) * | 2020-02-28 | 2022-11-01 | 深圳市亚辉龙生物科技股份有限公司 | SARS-CoV-2的重组RBD蛋白及其制备方法 |
US20210283243A1 (en) * | 2020-03-11 | 2021-09-16 | Ibio, Inc. | Lichenase-covid-19 based vaccine |
WO2021207948A1 (en) * | 2020-04-14 | 2021-10-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-sars-cov-2 antibodies and uses thereof |
US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
JP2023521618A (ja) * | 2020-04-01 | 2023-05-25 | チオジェネシス セラピューティクス, インコーポレイテッド | ベータコロナウイルス感染症の治療のためのシステアミン前駆体化合物 |
WO2021201679A1 (en) | 2020-04-01 | 2021-10-07 | Kiadis Pharma Intellectual Property B.V. | Compositions and methods targeting coronaviruses |
AU2020340881A1 (en) | 2020-04-02 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
US20230399384A1 (en) * | 2020-04-24 | 2023-12-14 | The Board Of Regents Of The University Of Texas System | Antibodies to coronavirus spike protein and methods of use thereof |
EP4144353A1 (en) * | 2020-04-30 | 2023-03-08 | FUJIFILM Toyama Chemical Co., Ltd. | Coronavirus infection therapeutic agent formed through combination of pyrazine derivative and another coronavirus infection therapeutic drug |
GB202007532D0 (en) * | 2020-05-20 | 2020-07-01 | Alchemab Therapeutics Ltd | Polypeptides |
WO2021238910A1 (en) * | 2020-05-25 | 2021-12-02 | Guo Bingshi | Anti-coronavirus spike protein antibodies and uses thereof |
CA3179819A1 (en) | 2020-05-26 | 2021-12-02 | Alina Baum | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
CN111606981B (zh) * | 2020-05-27 | 2022-02-08 | 中国医学科学院基础医学研究所 | Sars-cov冠状病毒s1蛋白多肽及其应用 |
EP4168440A1 (en) * | 2020-06-23 | 2023-04-26 | Navigo Proteins Gmbh | Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (sars-cov-2) |
KR20220013344A (ko) * | 2020-07-24 | 2022-02-04 | (주)셀트리온 | 코로나바이러스 슈퍼패밀리에 중화 활성을 갖는 결합 분자 |
WO2022026807A2 (en) * | 2020-07-30 | 2022-02-03 | Albert Einstein College Of Medicine | Antibodies targeting sars-cov-2 and uses thereof |
CN116322776A (zh) * | 2020-08-03 | 2023-06-23 | 詹森生物科技公司 | 用于病毒治疗剂中的多向生物转运的材料和方法 |
JP2023536935A (ja) * | 2020-08-07 | 2023-08-30 | ノヴェルジェン カンパニー リミテッド | コロナウイルスに対する抗ウイルス用組成物 |
KR20230058094A (ko) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략 |
WO2022054068A1 (en) * | 2020-09-14 | 2022-03-17 | Ramot At Tel-Aviv University Ltd. | Antibodies for the prevention, treatment and detection of coronavirus infection |
WO2022060906A1 (en) * | 2020-09-15 | 2022-03-24 | Duke University | Coronavirus antibodies and uses thereof |
CN116390945A (zh) * | 2020-09-24 | 2023-07-04 | 博德研究所 | 无细胞抗体工程化平台和针对SARS-CoV-2的中和抗体 |
CN112379087B (zh) * | 2020-10-21 | 2022-02-11 | 中国医学科学院医学生物学研究所 | 一种应用于新型冠状病毒灭活疫苗的裂解液及抗原解离的方法 |
AU2021385363A1 (en) | 2020-11-25 | 2023-06-08 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
IL303675A (en) | 2020-12-17 | 2023-08-01 | Regeneron Pharma | Production of protein thermal microgels |
TW202241497A (zh) * | 2021-01-05 | 2022-11-01 | 美商伊米若梅有限公司 | 針對SARS-CoV-2棘蛋白之抗體雞尾酒療法 |
EP4281542A1 (en) | 2021-01-20 | 2023-11-29 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
EP4281468A1 (en) * | 2021-01-22 | 2023-11-29 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Monoclonal antibodies against corovaviruses and uses thereof |
WO2022170126A2 (en) * | 2021-02-05 | 2022-08-11 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus s protein and uses thereof |
WO2022182662A1 (en) | 2021-02-23 | 2022-09-01 | 10X Genomics, Inc. | Compositions and methods for mapping antigen-binding molecule affinity to antigen regions of interest |
TW202246325A (zh) | 2021-03-03 | 2022-12-01 | 美商再生元醫藥公司 | 用於定量及修飾蛋白質黏度之系統及方法 |
WO2022187626A1 (en) | 2021-03-05 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments |
EP4308589A1 (en) * | 2021-03-15 | 2024-01-24 | Emory University | Sars-cov-2 antibodies and fragments, therapeutic uses, diagnostic uses, and compositions related thereto |
WO2022212654A2 (en) * | 2021-04-02 | 2022-10-06 | The Scripps Research Institute | Cross-reactive monoclonal antibodies against coronaviruses |
WO2022241200A1 (en) * | 2021-05-14 | 2022-11-17 | Vanderbilt University | Cross-reactive coronavirus antibodies |
EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
TW202321292A (zh) | 2021-07-14 | 2023-06-01 | 美商再生元醫藥公司 | 抗sars-cov-2-棘醣蛋白抗體及抗原結合片段 |
CA3227150A1 (en) * | 2021-07-23 | 2023-01-26 | The Trustees Of Columbia University In The City Of New York | Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use |
WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
AU2022359898A1 (en) | 2021-10-07 | 2024-03-21 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
CA3230984A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Systems and methods of ph modeling and control |
TW202330104A (zh) | 2021-10-26 | 2023-08-01 | 美商再生元醫藥公司 | 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法 |
WO2023178182A1 (en) | 2022-03-16 | 2023-09-21 | 10X Genomics, Inc. | Compositions and methods for detection and treatment of coronavirus infection |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
ES2529736T3 (es) * | 2003-04-10 | 2015-02-25 | Novartis Vaccines And Diagnostics, Inc. | Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS |
US7750123B2 (en) * | 2003-11-25 | 2010-07-06 | Dana Farber Cancer Institute, Inc. | Antibodies against SARS-CoV and methods of use thereof |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
WO2014045254A2 (en) | 2012-09-23 | 2014-03-27 | Erasmus University Medical Center Rotterdam | Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor |
CN103554244B (zh) * | 2013-05-09 | 2016-09-07 | 香雪集团(香港)有限公司 | 具有抑制呼吸道病毒感染的活性的肽及其应用和制备方法 |
CN103554235B (zh) * | 2013-06-17 | 2015-06-24 | 清华大学 | MERS-CoV病毒膜蛋白中的RBD片段及其编码基因和应用 |
KR20160145813A (ko) * | 2014-04-25 | 2016-12-20 | 다나-파버 캔서 인스티튜트 인크. | 중동 호흡기 증후군 코로나바이러스 중화 항체 및 이의 사용 방법 |
JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
AU2015266841C1 (en) * | 2014-05-30 | 2018-06-07 | Regeneron Pharmaceuticals, Inc. | Humanized dipeptidyl peptidase IV (DPP4) animals |
-
2015
- 2015-05-07 JO JOP/2015/0107A patent/JO3701B1/ar active
- 2015-05-19 MA MA040688A patent/MA40688A/fr unknown
- 2015-05-20 SG SG11201608567YA patent/SG11201608567YA/en unknown
- 2015-05-20 IL IL248392A patent/IL248392B2/en unknown
- 2015-05-20 BR BR112016025009-5A patent/BR112016025009B1/pt active IP Right Grant
- 2015-05-20 US US14/717,760 patent/US9718872B2/en active Active
- 2015-05-20 MY MYPI2016703768A patent/MY180741A/en unknown
- 2015-05-20 AU AU2015264189A patent/AU2015264189B2/en active Active
- 2015-05-20 KR KR1020167036178A patent/KR102371300B1/ko active IP Right Grant
- 2015-05-20 EP EP15726488.8A patent/EP3145539A1/en active Pending
- 2015-05-20 JP JP2016567890A patent/JP6934722B2/ja active Active
- 2015-05-20 CA CA2949438A patent/CA2949438A1/en active Pending
- 2015-05-20 EA EA201691877A patent/EA036023B1/ru unknown
- 2015-05-20 CN CN202111339577.1A patent/CN114057869A/zh active Pending
- 2015-05-20 WO PCT/US2015/031800 patent/WO2015179535A1/en active Application Filing
- 2015-05-20 MX MX2016015263A patent/MX2016015263A/es active IP Right Grant
- 2015-05-20 CN CN201580026696.8A patent/CN106414496B/zh active Active
-
2016
- 2016-10-13 ZA ZA2016/07047A patent/ZA201607047B/en unknown
- 2016-10-17 PH PH12016502064A patent/PH12016502064A1/en unknown
- 2016-11-17 CL CL2016002934A patent/CL2016002934A1/es unknown
-
2017
- 2017-06-26 US US15/633,589 patent/US10406222B2/en active Active
-
2019
- 2019-08-02 US US16/530,140 patent/US20190351049A1/en not_active Abandoned
-
2021
- 2021-06-01 JP JP2021092024A patent/JP7297814B2/ja active Active
-
2023
- 2023-04-04 JP JP2023060532A patent/JP2023085425A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016025009A2 (pt) | anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície | |
CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
BR112019002687A2 (pt) | receptores de antígeno quimérico que direcionam bcma e métodos de uso dos mesmos | |
ES2692773T3 (es) | Tratamientos para la fibrosis | |
BR112017000671A2 (pt) | moléculas com especificidade para cd79 e cd22 | |
BR112016030908A2 (pt) | moléculas com especificidade para cd45 e cd79 | |
CL2023000896A1 (es) | Receptores quiméricos de dll3 y métodos para su uso | |
BR112016024780A2 (pt) | composições e métodos relacionados com construtos de fc manipulados | |
EA201791675A1 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
BR112018006251A2 (pt) | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso | |
BR112018072723A2 (pt) | composição, e, métodos para tratar uma doença em um sujeito e para aumentar uma resposta imunológica em um sujeito | |
WO2017035430A3 (en) | Anti-alk antibodies and methods for use thereof | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
BR112018008103A2 (pt) | análogos de celastrol | |
BR112019020414A2 (pt) | composições e métodos para detectar e tratar câncer de próstata usando moléculas de ligação à progastrina | |
BR112018013268A2 (pt) | composições e métodos para detectar e tratar câncer gástrico | |
BR112018008900A8 (pt) | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas | |
BR112016015078A2 (pt) | método para prevenir ou tratar infecção por vírus influenza a h7n9, uso do anticorpo e composição farmacêutica | |
EA201792312A1 (ru) | Конструкции на основе калихеамицина и способы их применения | |
BR112018072697A2 (pt) | composição, e, método para tratar uma doença em um sujeito |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/05/2015, OBSERVADAS AS CONDICOES LEGAIS |